Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week High on Analyst Upgrade

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shares reached a new 52-week high during mid-day trading on Wednesday after Morgan Stanley raised their price target on the stock from $100.00 to $120.00. Morgan Stanley currently has an overweight rating on the stock. Arrowhead Pharmaceuticals traded as high as $88.11 and last traded at $88.4960, with a volume of 343079 shares changing hands. The stock had previously closed at $74.52.

ARWR has been the topic of several other research reports. Sanford C. Bernstein boosted their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Wednesday, July 1st. Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. JPMorgan Chase & Co. raised their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Finally, Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a “buy” rating and a $98.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $93.83.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.60% of the company’s stock.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Arrowhead reported topline Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran, with both studies meeting the primary endpoint of triglyceride reduction versus placebo; the drug also showed meaningful reductions in acute pancreatitis risk, which investors view as a major de-risking event. Article Title
• Positive Sentiment: Analysts responded favorably to the data, with Piper Sandler reaffirming an overweight rating and raising its price target to $126, and Morgan Stanley lifting its target to $120, reinforcing expectations for further upside if commercialization progresses. Article Title
• Positive Sentiment: Coverage highlighted Arrowhead’s stock move to a new 52-week high and described the plozasiran win as a validation of the company’s late-stage pipeline, with some commentary suggesting broader FDA approval and expanded commercialization potential. Article Title
• Neutral Sentiment: Additional reports noted that Arrowhead’s ARO-033 first-in-human trial showed early safety progress, which is constructive for the pipeline but less immediately important than the plozasiran catalyst. Article Title
• Negative Sentiment: No major negative company-specific news was provided in the recent items, though one market note flagged that the stock’s valuation has run up sharply, which could make further gains more dependent on execution and regulatory follow-through. Article Title

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Carolina Wealth Advisors LLC grew its holdings in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 154 shares during the period. CWM LLC raised its position in Arrowhead Pharmaceuticals by 1.4% during the fourth quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after acquiring an additional 168 shares in the last quarter. First Horizon Corp lifted its holdings in Arrowhead Pharmaceuticals by 36.2% in the first quarter. First Horizon Corp now owns 654 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 174 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 1.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after acquiring an additional 178 shares during the period. Finally, Optiver Holding B.V. boosted its position in Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Down 2.2%

The firm has a market cap of $12.22 billion, a price-to-earnings ratio of -40.36 and a beta of 1.26. The business’s 50 day moving average price is $77.76 and its 200 day moving average price is $69.86. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. During the same period in the previous year, the business posted $2.75 EPS. The business’s revenue was down 86.4% compared to the same quarter last year. On average, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.09 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.